QUALITATIVE EXPLORATION OF THE REAL-WORLD EXPERIENCES OF MEN RECEIVING OR REFUSING CHEMOTHERAPY (DOCETAXEL) FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

被引：0
|
作者：
Ito, T. [1 ]
Grant, L. [2 ]
Mills, A. [3 ]
Heselwood, A. [3 ]
Gater, A. [2 ]
机构：
[1] Janssen Cilag UK, High Wycombe, Bucks, England
[2] Adelphi Values Ltd, Bollington, Cheshire, England
[3] Adelphi Res UK, Bollington, Cheshire, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.295
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN212
引用
收藏
页码：A450 / A450
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [2] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Lage, Daniel E.
    Michaelson, Dror M.
    Lee, Richard J.
    Greer, Joseph A.
    Temel, Jennifer S.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Lage, Daniel E.
    Michaelson, M. Dror
    Lee, Richard J.
    Greer, Joseph A.
    Temel, Jennifer S.
    Sweeney, Christopher J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1181 - 1188
  • [4] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Daniel E. Lage
    M. Dror Michaelson
    Richard J. Lee
    Joseph A. Greer
    Jennifer S. Temel
    Christopher J. Sweeney
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1181 - 1188
  • [5] A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Heidegger, Isabel
    Bektic, Jasmin
    Kafka, Mona
    van den Bergh, Roderick C. N.
    Hunting, Jarmo C. B.
    Thomas, Anita
    Brandt, Maximilian P.
    Hoefner, Thomas
    Debedde, Eliott
    Thibault, Constance
    Ermacora, Paola
    Zattoni, Fabio
    Foti, Silvia
    Kretschmer, Alexander
    Ploussard, Guillaume
    Rodler, Severin
    von Amsberg, Gunhild
    Tilki, Derya
    Surcel, Christian
    Rosenzweig, Barak
    Gadot, Moran
    Gandaglia, Giorgio
    Dotzauer, Robert
    CANCER MEDICINE, 2021, 10 (18): : 6354 - 6364
  • [6] Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
    Goebell, P. J.
    Shah, R.
    Raina, R.
    Rege, S.
    Chen, S. L.
    Lee, V. E.
    Waldeck, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S660 - S661
  • [7] Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.
    Geynisman, Daniel M.
    Correa, Andres F.
    Ramamurthy, Chethan
    Beck, Robert J.
    Handorf, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Schwentner, Christian
    AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
  • [9] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia
    Goebell, Peter J.
    Raina, Rutika
    Chen, Stephanie
    Rege, Sanika
    Shah, Ruchit
    Grossman, Jamie Partridge
    Waldeck, A. Reginald
    FUTURE ONCOLOGY, 2024, 20 (14) : 903 - 918
12345